1Y Target$12.75Near-term target
5Y Target$17.86Compound horizon
10Y Target$26.25Long-dated conviction
FCF—TTM—FCF not applicable for this sector (bank / insurer / REIT) or data unavailable
Rev+33.3%TTM YoYARevenue +33.3% — hypergrowth, top decile
D/E0.19A-D/E 0.19 — conservative leverage, strong balance sheet
P/E15.2xB+P/E 15.2 — at or below S&P median, reasonable
PEG0.46proxyAPEG 0.46 — exceptional; paying well under fair value for growth · PEG proxy: P/E ÷ revenue growth % (true PEG requires forward EPS estimates, not in Finnhub free tier).
Why now
N/A · market cap $2.3b. Down 27% from 52-week high of $15.20 — deep drawdown territory. Revenue growing +33% — in hypergrowth territory. PEG 0.46 — paying under fair value for the growth rate.
Moat
Net margin 75% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma.
Risk
P/S 16.2x embeds aggressive forward growth — disappointing top-line guidance would compress the multiple hard. ROE 8% is below the long-run sustainable threshold of ~10% — capital efficiency would need to improve for the equity base to compound at the market rate.
Horizon
1-3 yr $12.75 (structural (no analyst coverage)) — fundamentals + valuation re-rating. 5 yr $17.86 at ~10% CAGR — compounding case rests on the competitive position widening. 10 yr $26.25 if current growth sustains into durable earnings power.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See
terms and
methodology for full disclosures.